Epizyme, Inc
EPZM
EPZM was delisted on the 11th of August, 2022.
136 hedge funds and large institutions have $2.25B invested in Epizyme, Inc in 2019 Q4 according to their latest regulatory filings, with 40 funds opening new positions, 39 increasing their positions, 39 reducing their positions, and 18 closing their positions.
1,068% more call options, than puts
Call options by funds: $83.6M | Put options by funds: $7.16M
172% more capital invested
Capital invested by funds: $828M → $2.25B (+$1.43B)
122% more first-time investments, than exits
New positions opened: 40 | Existing positions closed: 18
100% more funds holding in top 10
Funds holding in top 10: 5 → 10 (+5)
18% more funds holding
Funds holding: 115 → 136 (+21)
0% more repeat investments, than reductions
Existing positions increased: 39 | Existing positions reduced: 39
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
RM
RP Management
New York
|
+$99M |
| 2 |
Primecap Management
Pasadena,
California
|
+$32.4M |
| 3 |
T. Rowe Price Associates
Baltimore,
Maryland
|
+$20.4M |
| 4 |
AG
Artal Group
Luxembourg
|
+$11.1M |
| 5 |
Janus Henderson Group
London,
|
+$8.38M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Millennium Management
New York
|
-$17.2M |
| 2 |
FCMI
Foresite Capital Management II
Larkspur,
California
|
-$13.3M |
| 3 |
Citadel Advisors
Miami,
Florida
|
-$8.19M |
| 4 |
Fidelity Investments
Boston,
Massachusetts
|
-$6.38M |
| 5 |
State Street
Boston,
Massachusetts
|
-$5.82M |
EPZM Hedge Fund Activity: Q4 2019 in Review
136 of the 5,092 institutional investors tracked by Wall St. Rank reported a position in Epizyme, Inc (EPZM) for Q4 2019, worth a combined $2.25B — up 172% from $828M a quarter earlier.
Buyers outnumbered sellers: 40 funds opened new EPZM positions and 18 closed out — a net gain of 22 holders — while 39 added to existing stakes and 39 trimmed.
The largest buyer was RP Management, opening a new position worth an estimated $99M. The largest seller was Millennium Management, cutting an estimated $17.2M.
- 136 institutional investors held Epizyme, Inc (EPZM) as of Q4 2019, up from 115 in Q3 2019.
- Funds reported $2.25B of Epizyme, Inc stock for Q4 2019, up 172% quarter-over-quarter.
- 40 funds opened new Epizyme, Inc positions in Q4 2019 and 18 closed out, a net change of +22 holders.
- The largest Epizyme, Inc buyer in Q4 2019 was RP Management, an estimated $99M added.
- The largest Epizyme, Inc seller in Q4 2019 was Millennium Management, an estimated $17.2M sold.
Based on aggregated 13F filings for Q4 2019.